Detection of minimal residual disease: Relevance for diagnosis and treatment of human malignancies

Annual Review of Medicine

Volumn 49, Issue , 1998, Pages 111-122

  Hirsch Ginsberg, Cheryl ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

FISH; Immunophenotyping; Minimal residual disease; PCR; Southern blotting

Indexed keywords

BONE MARROW; BONE MARROW TRANSPLANTATION; CHIMERA; CYTOGENETICS; HUMAN; LYMPH NODE; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; SOUTHERN BLOTTING; TUMOR CELL;

EID: 0031959271     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.49.1.111     Document Type: Review

References (16)

1. Hirsch-Ginsberg C, Huh Y, Kagan J, et al. 1993. Advances in the diagnosis of acute leukemia. Hematology/Oncology Clinics of North America, ed. C Bloomfield, GP Herzig, pp. 1-46. Philadelphia: Saunders
2. Biondi A, Rambaldi A. 1996. Molecular diagnosis and monitoring of acute myeloid leukemia. Leuk. Res. 20:801-7
3. Bishop JF. 1997. The treatment of acute myeloid leukemia. Semin. Oncol. 24: 57-69
4. Brisco MJ, Hughes E, Neoh SH, et al. 1996. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87: 5261-56
5. Camitta B, Pullen J, Murphy S. 1997. Biology and treatment of acute lymphocytic leukemia in children. Semin. Oncol. 24: 83-91
6. Campana D, Pui CH. 1995. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85:1416-34
7. Cave H, Bakkus M, Suciu S, et al. 1995. Significance of the quantitation of minimal residual disease by PCR amplification of IgH and TCR gene rearrangements in childhood ALL. Blood 86(Suppl.): 178a (Abstr.)
8. Cortes J, Talpaz M, Kantarjian H. 1996. Chronic myelogenous leukemia: a review. Am. J. Med. 100:555-70
9. Fenaux P, Chomienne C, Degos L. 1997. Acute promyelocytic leukemia: biology and treatment. Semin. Oncol. 24: 92-102
10. Inoue K, Ogawa H, Yamagami T, et al. 1996. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms Tumor Gene) expression levels. Blood 88:2267-78
11. Ito Y, Miyamura K. 1994. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: Is molecular remission a milestone for achieving a cure? Leuk. Lymph. 16:57-64
12. Carlo-Stella C, Mangoni L, Dotti GP, et al. 1995. Techniques for detection of minimal residual disease. Leuk. Lymph 18 (Suppl.1):75-80
13. Estey EH, Keating MJ, Dixon DO, et al. 1987. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol. Pathol. 1:203-8
14. Mrozek K, Heinonen K, de la Chapelle A, et al. 1997. Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol. 24:17-31
15. Seong DC, Kantarjian H, Ro JY, et al. 1995. Hypermetaphase flourescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86:2343-49
16. Tkachuk DC, Westbrook CA, Andreef M, et al. 1990. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 250:559-62